A number of brokers keep a list of the ASX 200 shares that they rate above all others.
Two blue chips that have made it onto these lists this month are named below. Here's why analysts are bullish on them:
ResMed Inc (ASX: RMD)
The first blue chip ASX 200 share that has been given the thumbs up is ResMed.
Morgans is bullish on the the sleep treatment company. It doesn't believe the emergence of weight loss drugs like Ozempic is a threat and continues to forecast strong long-term growth. The broker said:
While weight loss drugs have grabbed headlines and investor attention, we see these products having little impact on the large, underserved sleep disorder breathing market, and do not view them as category killers. Although quarters are likely to remain volatile, nothing changes our view that the company remains well placed and uniquely positioned as it builds a patient-centric, connected-care digital platform that addresses the main pinch points across the healthcare value chain.
Morgans has an add rating and a $32.74 price target on ResMed's shares.
Seven Group Holdings Ltd (ASX: SVW)
Diversified investment company Seven Group could be another ASX 200 blue chip to buy.
It is a best buy for analysts at Bell Potter. They believe the company is well-positioned for the future thanks to the market-leading businesses in its portfolio and favourable tailwinds. The broker explains:
SVW's businesses and investments are market leaders in their respective industries, with scale, brand and industry expertise underpinning commercial advantages that are hard to replicate by competitors. We are positive on the near-term outlook for mining production, engineering construction and transitional energy markets; critical minerals mining, renewable project construction and expected domestic and international gas supply shortfalls represent longer-term tailwinds.
Bell Potter currently has a buy rating and a $33 price target on the company's shares.
